Thomas Nerreter

2.2k total citations · 1 hit paper
24 papers, 1.1k citations indexed

About

Thomas Nerreter is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Thomas Nerreter has authored 24 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 12 papers in Immunology and 11 papers in Molecular Biology. Recurrent topics in Thomas Nerreter's work include CAR-T cell therapy research (16 papers), Immune Cell Function and Interaction (8 papers) and Viral Infectious Diseases and Gene Expression in Insects (7 papers). Thomas Nerreter is often cited by papers focused on CAR-T cell therapy research (16 papers), Immune Cell Function and Interaction (8 papers) and Viral Infectious Diseases and Gene Expression in Insects (7 papers). Thomas Nerreter collaborates with scholars based in Germany, United States and United Kingdom. Thomas Nerreter's co-authors include Michael Hudecek, Hermann Einsele, Julian Rydzek, Katrin Mestermann, Theodoros Giavridis, Andreas Mades, Michel Sadelain, Silke Frenz, Justus Weber and Sören Doose and has published in prestigious journals such as Science, Nature Communications and Blood.

In The Last Decade

Thomas Nerreter

22 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells

2019 379 citations Katrin Mestermann, Theodoros Giavridis et al. Science Translational Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Nerreter Germany	13	853	387	327	322	235	24	1.1k
Maiko Matsushita Japan	11	857 1.0×	344 0.9×	418 1.3×	269 0.8×	302 1.3×	39	1.1k
Lekha Mikkilineni United States	12	783 0.9×	400 1.0×	236 0.7×	197 0.6×	157 0.7×	26	980
Christopher D. Chien United States	16	702 0.8×	450 1.2×	302 0.9×	172 0.5×	249 1.1×	32	1.1k
Scott E. James United States	9	1.0k 1.2×	374 1.0×	482 1.5×	304 0.9×	392 1.7×	12	1.2k
Giacomo Oliveira Italy	14	854 1.0×	405 1.0×	802 2.5×	182 0.6×	237 1.0×	26	1.4k
Yinmeng Yang United States	9	662 0.8×	338 0.9×	325 1.0×	174 0.5×	210 0.9×	18	877
Bruno L. Cadilha Germany	10	945 1.1×	393 1.0×	560 1.7×	277 0.9×	183 0.8×	16	1.3k
Myo Htut United States	15	777 0.9×	621 1.6×	206 0.6×	164 0.5×	115 0.5×	48	1.0k
Haiying Qin United States	19	1.6k 1.9×	742 1.9×	654 2.0×	468 1.5×	558 2.4×	41	2.1k
Carmen S. Yong Australia	12	1.2k 1.4×	455 1.2×	848 2.6×	303 0.9×	313 1.3×	21	1.7k

Countries citing papers authored by Thomas Nerreter

Since Specialization

Citations

This map shows the geographic impact of Thomas Nerreter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Nerreter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Nerreter more than expected).

Fields of papers citing papers by Thomas Nerreter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Nerreter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Nerreter. The network helps show where Thomas Nerreter may publish in the future.

Co-authorship network of co-authors of Thomas Nerreter

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Nerreter. A scholar is included among the top collaborators of Thomas Nerreter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Nerreter. Thomas Nerreter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Weber, Justus, Charis Kalogirou, Jörg Lehmann, et al.. (2025). ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice. Cell Reports Medicine. 6(10). 102400–102400.

Riester, Zeno, Nicole Seifert, Arindam Ghosh, et al.. (2025). Co-expression of an adapter CAR retains efficacy of CAR T cells after single and dual antigen loss in lymphoma. Molecular Therapy. 34(2). 867–884.

Ghosh, Arindam, Mara Meub, Dominic A. Helmerich, et al.. (2025). Decoding the molecular interplay of CD20 and therapeutic antibodies with fast volumetric nanoscopy. Science. 387(6730). eadq4510–eadq4510. 8 indexed citations

Nerreter, Thomas, Carsten Hagemann, Ralf‐Ingo Ernestus, et al.. (2023). Characterization and Optimization of the Tumor Microenvironment in Patient-Derived Organotypic Slices and Organoid Models of Glioblastoma. Cancers. 15(10). 2698–2698. 5 indexed citations

Peng, Haiyong, et al.. (2022). ROR1-targeting switchable CAR-T cells for cancer therapy. Oncogene. 41(34). 4104–4114. 22 indexed citations

García‐Guerrero, Estefanía, Ralph Götz, Sören Doose, et al.. (2020). Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab. Leukemia. 35(1). 201–214. 53 indexed citations

Prommersberger, Sabrina, Michael Hudecek, & Thomas Nerreter. (2020). Antibody‐Based CAR T Cells Produced by Lentiviral Transduction. Current Protocols in Immunology. 128(1). e93–e93. 17 indexed citations

Dragon, Anna Christina, Katharina Zimmermann, Thomas Nerreter, et al.. (2020). CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation. Journal for ImmunoTherapy of Cancer. 8(2). e000736–e000736. 38 indexed citations

Göttlich, Claudia, Johanna Kühnemundt, Thomas Schwarz, et al.. (2019). ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models. JCI Insight. 4(18). 154 indexed citations

10.

Mestermann, Katrin, Theodoros Giavridis, Justus Weber, et al.. (2019). The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Science Translational Medicine. 11(499). 379 indexed citations breakdown →

11.

García‐Cadenas, Irene, Thomas Nerreter, Simone Thomas, et al.. (2018). CAR T-cells targeting FLT3 have potent activity against FLT3−ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib. Leukemia. 32(5). 1168–1179. 153 indexed citations

12.

Rydzek, Julian, Thomas Nerreter, Haiyong Peng, et al.. (2018). Chimeric Antigen Receptor Library Screening Using a Novel NF-κB/NFAT Reporter Cell Platform. Molecular Therapy. 27(2). 287–299. 40 indexed citations

13.

García‐Cadenas, Irene, Thomas Nerreter, Jorge Sierra, et al.. (2018). FLT3 Inhibitor Treatment Increases FLT3 Expression That Exposes FLT3-ITD+ AML Blasts to Elimination By FLT3 CAR-T Cells. Blood. 132(Supplement 1). 903–903. 6 indexed citations

14.

Lohmeyer, Jürgen, et al.. (2018). Sorafenib paradoxically activates the RAS/RAF/ERK pathway in polyclonal human NK cells during expansion and thereby enhances effector functions in a dose- and time-dependent manner. Clinical & Experimental Immunology. 193(1). 64–72. 23 indexed citations

15.

Nerreter, Thomas, et al.. (2017). Robust 8-color flow cytometry panel reveals enhanced effector function of NKG2C+ CD57+ FcεRγ− NK cells in CMV seropositive human blood donors. Immunobiology. 222(5). 719–725. 4 indexed citations

16.

Peng, Haiyong, Thomas Nerreter, Junpeng Qi, et al.. (2017). Mining Naïve Rabbit Antibody Repertoires by Phage Display for Monoclonal Antibodies of Therapeutic Utility. Journal of Molecular Biology. 429(19). 2954–2973. 38 indexed citations

17.

Nerreter, Thomas, et al.. (2014). Dasatinib enhances migration of monocyte-derived dendritic cells by reducing phosphorylation of inhibitory immune receptors Siglec-9 and Siglec-3. Experimental Hematology. 42(9). 773–782.e3. 9 indexed citations

18.

Michaelis, Martin, et al.. (2014). Karanjin interferes with ABCB1, ABCC1, and ABCG2. Journal of Pharmacy & Pharmaceutical Sciences. 17(1). 92–92. 25 indexed citations

19.

Michaelis, Martin, Florian Rothweiler, Thomas Nerreter, et al.. (2014). Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression. BMC Research Notes. 7(1). 710–710. 12 indexed citations

20.

Nerreter, Thomas, et al.. (2013). Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitro. Experimental Hematology. 41(7). 604–614.e4. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact